<SEC-DOCUMENT>0001193125-25-241754.txt : 20251016
<SEC-HEADER>0001193125-25-241754.hdr.sgml : 20251016
<ACCEPTANCE-DATETIME>20251016205253
ACCESSION NUMBER:		0001193125-25-241754
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20251016
DATE AS OF CHANGE:		20251016

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Astria Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001454789
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-88910
		FILM NUMBER:		251398790

	BUSINESS ADDRESS:	
		STREET 1:		22 BOSTON WHARF ROAD
		STREET 2:		10TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
		BUSINESS PHONE:		617-349-1971

	MAIL ADDRESS:	
		STREET 1:		22 BOSTON WHARF ROAD
		STREET 2:		10TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CATABASIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20090127

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PERCEPTIVE ADVISORS LLC
		CENTRAL INDEX KEY:			0001224962
		ORGANIZATION NAME:           	
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		51 ASTOR PLACE, 10TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10003
		BUSINESS PHONE:		646-205-5300

	MAIL ADDRESS:	
		STREET 1:		51 ASTOR PLACE, 10TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10003
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001224962</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>6</amendmentNo>
      <securitiesClassTitle>Common Stock, par value $0.001 per share</securitiesClassTitle>
      <dateOfEvent>10/14/2025</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001454789</issuerCIK>
        <issuerCUSIP>04635X102</issuerCUSIP>
        <issuerName>Astria Therapeutics, Inc.</issuerName>
        <address>
          <street1 xmlns="http://www.sec.gov/edgar/common">22 Boston Wharf Road</street1>
          <street2 xmlns="http://www.sec.gov/edgar/common">10th Floor</street2>
          <city xmlns="http://www.sec.gov/edgar/common">Boston</city>
          <stateOrCountry xmlns="http://www.sec.gov/edgar/common">MA</stateOrCountry>
          <zipCode xmlns="http://www.sec.gov/edgar/common">02210</zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Alexander Rakitin</personName>
          <personPhoneNum>(646) 205-5340</personPhoneNum>
          <personAddress>
            <street1 xmlns="http://www.sec.gov/edgar/common">51 Astor Place, 10th Floor</street1>
            <city xmlns="http://www.sec.gov/edgar/common">New York</city>
            <stateOrCountry xmlns="http://www.sec.gov/edgar/common">NY</stateOrCountry>
            <zipCode xmlns="http://www.sec.gov/edgar/common">10003</zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0001224962</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Perceptive Advisors LLC</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>AF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>6485420</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>6485420</sharedDispositivePower>
        <aggregateAmountOwned>6485420</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>11.5</percentOfClass>
        <typeOfReportingPerson>IA</typeOfReportingPerson>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001164426</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Joseph Edelman</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>AF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>X1</citizenshipOrOrganization>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>6485420</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>6485420</sharedDispositivePower>
        <aggregateAmountOwned>6485420</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>11.5</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001249675</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Perceptive Life Sciences Master Fund, Ltd.</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>WC</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>E9</citizenshipOrOrganization>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>4873721</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>4873721</sharedDispositivePower>
        <aggregateAmountOwned>4873721</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>8.6</percentOfClass>
        <typeOfReportingPerson>CO</typeOfReportingPerson>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001757940</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Perceptive Xontogeny Venture Fund, L.P.</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>WC</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>1611699</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>1611699</sharedDispositivePower>
        <aggregateAmountOwned>1611699</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>2.9</percentOfClass>
        <typeOfReportingPerson>CO</typeOfReportingPerson>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Common Stock, par value $0.001 per share</securityTitle>
        <issuerName>Astria Therapeutics, Inc.</issuerName>
        <issuerPrincipalAddress>
          <street1 xmlns="http://www.sec.gov/edgar/common">22 Boston Wharf Road</street1>
          <street2 xmlns="http://www.sec.gov/edgar/common">10th Floor</street2>
          <city xmlns="http://www.sec.gov/edgar/common">Boston</city>
          <stateOrCountry xmlns="http://www.sec.gov/edgar/common">MA</stateOrCountry>
          <zipCode xmlns="http://www.sec.gov/edgar/common">02210</zipCode>
        </issuerPrincipalAddress>
      </item1>
      <item6>
        <contractDescription>Item 6 of the Schedule 13D is amended and supplemented as follows:

On October 14, 2025, the Master Fund and Perceptive Xontogeny each entered into a Voting and Support Agreement (the "Voting Agreement") with BioCryst Pharmaceuticals, Inc. ("BioCryst"). Pursuant to the Voting Agreement, the Master Fund and Perceptive Xontogeny each agreed to vote their respective shares of Common Stock in favor of the adoption of the merger agreement between BioCryst, the Issuer, and Axel Merger Sub, Inc. dated October 14, 2025 (the "Merger Agreement") with respect to the proposed acquisition of the Issuer by BioCryst (the "Merger") and the approval of the transactions contemplated thereby, and, subject to certain exceptions, not to transfer their shares of Common Stock prior to the earlier of the effective time of the Merger and the termination of the Merger Agreement. The Master Fund and Perceptive Xontogeny each also consented to the treatment of their respective shares of Series X Convertible Preferred Stock and Warrants as set forth in the Merger Agreement. The Voting Agreements will terminate upon the earlier of the effective time of the Merger, their termination by written notice from BioCryst, any amendment of any term or provision of the Merger Agreement that reduces the consideration to be received by holders of Common Stock, and the termination of the Merger Agreement.

The foregoing description of the Voting Agreements is qualified in its entirety by reference to the terms of the agreements, the form of which is filed as Exhibit 8 to this Schedule 13D and incorporated by reference into this Item 6.
</contractDescription>
      </item6>
      <item7>
        <filedExhibits>Item 7 of the Schedule 13D is amendmed and supplemented as follows:

Exhibit 8 Form of Voting and Support Agreement (incorporated by reference to Exhibit 99.1 to Astria Therapeutics, Inc.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 14, 2025)</filedExhibits>
      </item7>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Perceptive Advisors LLC</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Joseph Edelman</signature>
          <title>Joseph Edelman, Managing Member</title>
          <date>10/16/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Joseph Edelman</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Joseph Edelman</signature>
          <title>Joseph Edelman</title>
          <date>10/16/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Perceptive Life Sciences Master Fund, Ltd.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Joseph Edelman</signature>
          <title>By: Perceptive Advisors LLC, By: Joseph Edelman, Managing Member</title>
          <date>10/16/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Perceptive Xontogeny Venture Fund, L.P.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Joseph Edelman</signature>
          <title>By: Perceptive Xontogeny Ventures GP, LLC; By: Joseph Edelman, Managing Member</title>
          <date>10/16/2025</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
